This is manifested in the suppression of the anti-inflammatory activity of MUC1 due to pro-inflammatory cytokines that have passed the hematosalivary barrier and are activated by oncogenic processes occurring in breast cancer. This evidence concerns the gene MUC1 and breast cancer.